Weiss Ratings Reaffirms “Sell (E+)” Rating for InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX)‘s stock had its “sell (e+)” rating restated by Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports.

Separately, HC Wainwright initiated coverage on shares of InflaRx in a research note on Tuesday, September 2nd. They issued a “buy” rating and a $6.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $6.20.

InflaRx Trading Down 2.3%

Shares of NASDAQ IFRX opened at $1.25 on Tuesday. The stock has a market cap of $83.91 million, a price-to-earnings ratio of -1.56 and a beta of 1.40. InflaRx has a 52 week low of $0.71 and a 52 week high of $2.82. The company’s 50-day moving average price is $1.25 and its 200 day moving average price is $1.14.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.24) EPS for the quarter, meeting analysts’ consensus estimates of ($0.24). The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.02 million. As a group, research analysts expect that InflaRx will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IFRX. XTX Topco Ltd purchased a new position in InflaRx in the 1st quarter valued at about $38,000. DAFNA Capital Management LLC purchased a new position in InflaRx in the 1st quarter valued at about $459,000. Cubist Systematic Strategies LLC lifted its holdings in shares of InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after acquiring an additional 7,616 shares during the period. 683 Capital Management LLC lifted its holdings in shares of InflaRx by 26.8% during the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock worth $2,678,000 after acquiring an additional 555,000 shares during the period. Finally, Woodline Partners LP purchased a new position in shares of InflaRx during the 1st quarter worth about $766,000. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.